Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women

Stroke

Volumn 33, Issue 12, 2002, Pages 2762-2768

  Austin, Harland ^a,b,k   Chimowitz, Marc I ^b   Hill, Holly A ^b   Chaturvedi, Seemant ^c   Wechsler, Lawrence R ^d   Wityk, Robert J ^e   Walz, Elizabeth ^f   Wilterdink, Janet L ^g   Coull, Bruce ^h   Sila, Cathy A ⁱ   Mitsias, Panos ^j   Evatt, Bruce ^a   Craig Hooper, W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g RHODE ISLAND HOSPITAL   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

Coagulation; Factor V; Genetics; Stroke

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ALLELE; ARTERY OCCLUSION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENE POOL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; STROKE; THROMBOGENESIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; CAUSALITY; CEREBROVASCULAR ACCIDENT; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES; VARIATION (GENETICS);

EID: 0036903587     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000038094.79901.3B     Document Type: Article

References (36)

1. Hart RG, Benavente O, Stroke, part I: A clinical update on prevention. Am Farm Physician. 1999;59:2475-2482.
2. Stern BJ, Kittner S, Sloan M, Meyd C, Buchholz D, Rigamonti D, Woody R, Meyerhoff J, Bell W, Price T. Stroke in the young, parts I and II Md Med J. 1991;40:453-462, 565-571.
3. Bogousslavsky J, Pierre P, Ischemic stroke in patients under 45. Neurol Clin. 1992;10:113-124.
4. Foulkes MR, Wolf PA, Price TR, Mohr JP, Hier DB, The Stroke Data Bank: Design, methods, and baseline characteristics. Stroke. 1988;19: 547-554.
5. Hart RG, Kanter MC, Hematologic disorders and ischemic stroke: A selective review, Stroke. 1990;21:1111-1121.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of tbrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
7. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
8. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3398-3703.
9. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res. 1999;93:1-8.
10. Margaglione M, Brancaccio V, Giuliani N, Andrea D, Cappucci GG, Iannaccone L, Vecchione F, Grandone E, Di Minno G. Increased risk for venous thrombosis in carriers of prothrombin G→A20210 gene variant. Ann Intern Med. 1998;129:89-93.
11. Chimowitz MI, Furlan J, Sila CA, Paranandi L, Beck GJ. Etiology of motor or sensory stroke: A prospective study of the predictive value of clinical and radiologic features. Ann Neurol. 1991;30:519-525.
12. Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A. Armstrong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke. 1993; 24:1015-1019.
13. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH, Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, Van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:11-113.
15. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, Phillips DJ, Whilsett C, Rawlins P, Evatt BL. The role of tPA and PAI-1 4G/SG polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000; 99:223-230.
16. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the beta- fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost. 1991;65:487-490.
17. Van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, deJong PTVM, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction: The Rotterdam study. Circulation 1997;95:2623-2627.
18. Cambien F, Poirier O, Lecert L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al. Deletion polymorphism in the gene for angiotensin-convening-enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
19. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996;2:41-45.
20. Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK. Whitsett C, Rawlins P, Evatt BL. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African-Americans. Chest. 1999;116:880-886.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc: 1989.
22. Stata Statistical Software: Release 7.0. College Station, Tex: Stata Corp; 2001.
23. Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Kosch A, Gottl-Nowak U. Symptomatic ischemic stroke in full-term neonates: Role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31: 2437-2441.
24. Gottl-Nowak U, Strater R, Heinecke A, Junker R, Koch HG, Scbuierer G, von Eckardstein A. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94: 3678-3682.
25. Longstreth WT, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunatban TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577-580.
26. Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaff M, Annichino-Bizzacchi JM, Arruda VR. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000;83:229-233.
27. Markus HS, Barley J, Lunt R, Bland M, Jeffery S, Carter ND, Brown MM. Angiotensin-convening enzyme gene deletion polymorphism: A new risk factor for lacunar stroke but not carotid atberoma. Stroke. 1995;26:1329-1333.
28. Ueda S, Weir CJ, Inglis GC, Murray GD, Muir KW, Lees KR. Lack of association between angiotensin convening enzyme gene insertion/deletion polymorphism and stroke. J Hypertens. 1995;13:1597-1601.
29. Sharma P, Carter ND, Barley J, Brown MM. Molecular approach to assessing the genetic risk of cerebral infarction: Deletion polymorphism in the gene encoding angiotensin 1-converting enzyme. J Hum Hypertens. 1994;8:645-648.
30. Perry IJ. Homocysteine and risk of stroke. J Cardiovasc Risk. 1999;6: 235-240.
31. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation. 1998;98:2520-2526.
32. Endier G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promoter region of the plasminogen activator inhibitor I (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110:469-471.
33. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Loncet. 1994;343:940-943.
34. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler Thromb Vasc Biol. 1997;17: 3321-3325.
35. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B. Hallmans G. Tissue plasminogen activator/plasminogen activator inhibitor-1 and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31: 26-32.
36. Zunker P, Schick A, Padro T, Kienast J, Phillips A, Ringelstein EB. Tissue plasminogen activator and plasminogen activator in patients with acute ischemic stroke: Relation to stroke etiology. Neurol Res. 1999;21:727-732.